These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38835507)

  • 1. The future of cancer therapy: exploring the potential of patient-derived organoids in drug development.
    Avci CB; Bagca BG; Shademan B; Takanlou LS; Takanlou MS; Nourazarian A
    Front Cell Dev Biol; 2024; 12():1401504. PubMed ID: 38835507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
    Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
    Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
    Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.
    Khorsandi D; Yang JW; Foster S; Khosravi S; Hosseinzadeh Kouchehbaghi N; Zarei F; Lee YB; Runa F; Gangrade A; Voskanian L; Adnan D; Zhu Y; Wang Z; Jucaud V; Dokmeci MR; Shen X; Bishehsari F; Kelber JA; Khademhosseini A; de Barros NR
    Adv Healthc Mater; 2024 Aug; 13(21):e2302331. PubMed ID: 38359321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.
    Li L; Selaru FM
    Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Cancer Organoids for Precision Oncology Treatment.
    Pernik MN; Bird CE; Traylor JI; Shi DD; Richardson TE; McBrayer SK; Abdullah KG
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34067714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
    Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S
    Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy.
    Wu W; Li X; Yu S
    Acta Biomater; 2022 Jul; 146():23-36. PubMed ID: 35533925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
    Bi J; Newtson AM; Zhang Y; Devor EJ; Samuelson MI; Thiel KW; Leslie KK
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
    Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
    Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
    Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
    Merrill NM; Kaffenberger SD; Bao L; Vandecan N; Goo L; Apfel A; Cheng X; Qin Z; Liu CJ; Bankhead A; Wang Y; Kathawate V; Tudrick L; Serhan HA; Farah Z; Ellimoottil C; Hafez KS; Herrel LA; Montgomery JS; Morgan TM; Salami SS; Weizer AZ; Ulintz PJ; Day ML; Soellner MB; Palmbos PL; Merajver SD; Udager AM
    Eur Urol; 2024 Aug; ():. PubMed ID: 39155193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.
    He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J
    Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.